{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T10:33:58Z","timestamp":1794134038523,"version":"4.8.0"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The choice of oral anticoagulants for patients with Chronic Kidney Disease (CKD) combined with venous thromboembolism (VTE) or atrial fibrillation (AF) remains controversial.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To compare the efficacy and safety of warfarin and direct oral anticoagulants (DOACs) in the treatment of CKD with atrial fibrillation or venous thromboembolism.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Relevant publications were sourced from databases like PubMed, Embase, Web of Science, Cochrane Library, and ClinicalTrials.gov up to 30 June 2024. Only RCTs assessing the efficacy and safety of warfarin and DOACs for treating CKD with AF or VTE were included in the meta-analysis. The review outcomes are thrombosis recurrence or VTE-related deaths and major bleeding for CKD patients with VTE, and stroke or systemic embolism and major bleeding for CKD patients with AF. The risk of bias in all included studies was evaluated using the Cochrane Collaboration\u2019s tool.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>After reviewing 540 studies, 15 randomized controlled trials (RCTs) with 16,361 participants were included. The study found that DOACs reduced the risk of hemorrhagic stroke compared to warfarin in patients with AF and CKD (RR = 0.455, 95% CI: 0.275\u20130.752, P = 0.002). There was no significant difference in ischemic stroke incidence between the two. DOACs also lowered the risk of major bleeding in patients with AF and CKD compared to warfarin (RR = 0.604, 95% CI: 0.442\u20130.825, P = 0.002), and significantly reduced the risk of intracranial bleeding (RR = 0.424, 95% CI: 0.287\u20130.626, P &amp;lt; 0.001). All five studies reported recurrent VTE or VTE-related deaths, showing no significant difference between warfarin and DOAC groups (RR = 0.663, 95% CI: 0.409\u20131.073, P = 0.094), Patients with renal dysfunction on either treatment had similar risks of major bleeding events (RR = 0.543, 95% CI: 0.209\u20131.407, P = 0.208).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>DOACs demonstrate superior efficacy and safety compared to warfarin in patients with AF and CKD. Additionally, DOACs exhibit comparable efficacy and safety to warfarin in patients with VTE and CKD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic Review Registration<\/jats:title><jats:p><jats:ext-link>http:\/\/www.clinicaltrials.gov<\/jats:ext-link>, identifier (CRD42024510727).<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1615284","type":"journal-article","created":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T22:10:20Z","timestamp":1756419020000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Efficacy and safety of oral anticoagulants in the treatment of chronic kidney disease with atrial fibrillation or venous thromboembolism: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Qinan","family":"Yin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingyue","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqing","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujie","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizhu","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youjin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Bian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1053\/j.gastro.2016.12.018","article-title":"Gastrointestinal safety of direct oral anticoagulants: a large population-based study","volume":"152","author":"Abraham","year":"2017","journal-title":"Gastroenterology"},{"key":"B2","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1302507","article-title":"Oral apixaban for the treatment of acute venous thromboembolism","volume":"369","author":"Agnelli","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"e003998","DOI":"10.1161\/CIRCOUTCOMES.117.003998","article-title":"Gastrointestinal bleeding with edoxaban versus warfarin: results from the ENGAGE AF-TIMI 48 trial (effective anticoagulation with factor xa next generation in atrial fibrillation-thrombolysis in myocardial infarction)","volume":"11","author":"Aisenberg","year":"2018","journal-title":"Circ. Cardiovasc Qual. Outcomes"},{"key":"B4","doi-asserted-by":"publisher","first-page":"58","DOI":"10.47583\/ijpsrr.2024.v84i05.009","article-title":"Comparison of efficacy and safety of apixaban and warfarin in patients with atrial fibrillation and chronic kidney disease: a randomised controlled trial","volume":"84","author":"Arun Kumar","year":"2024","journal-title":"Int. J. Pharm. Sci. Rev. Res."},{"key":"B5","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1002\/clc.23196","article-title":"Anticoagulation in chronic kidney disease: from guidelines to clinical practice","volume":"42","author":"Aursulesei","year":"2019","journal-title":"Clin. Cardiol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1161\/CIRCULATIONAHA.116.022361","article-title":"Impact of renal function on outcomes with edoxaban in the ENGAGE AF-TIMI 48 trial","volume":"134","author":"Bohula","year":"2016","journal-title":"Circulation"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.18087\/cardio.2020.11.n1322","article-title":"Safety performance of rivaroxaban versus warfarin in patients with atrial fibrillation and advanced chro-nic kidney disease","volume":"60","author":"Chashkina","year":"2020","journal-title":"Kardiologiia"},{"key":"B8","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s40261-021-01016-7","article-title":"Efficacy and safety of direct oral anticoagulants vs warfarin in patients with chronic kidney disease and dialysis patients: a systematic review and meta-analysis","volume":"41","author":"Chen","year":"2021","journal-title":"Clin. Drug Investig."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1681\/ASN.2020111566","article-title":"Safety and efficacy of vitamin K antagonists versus rivaroxaban in hemodialysis patients with atrial fibrillation: a multicenter randomized controlled trial","volume":"32","author":"De Vriese","year":"2021","journal-title":"J. Am. Soc. Nephrol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s11239-016-1437-1","article-title":"Venous thromboembolism in chronic kidney disease: epidemiology, the role of proteinuria, CKD severity and therapeutics","volume":"43","author":"Dobrowolski","year":"2017","journal-title":"J. Thromb. Thrombolysis"},{"key":"B11","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/j.0006-341x.2000.00455.x","article-title":"Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis","volume":"56","author":"Duval","year":"2000","journal-title":"Biometrics"},{"key":"B12","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1159\/000535546","article-title":"Anticoagulation in patients with chronic kidney disease","volume":"55","author":"Elenjickal","year":"2024","journal-title":"Am. J. Nephrol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1471-2288-7-5","article-title":"Inclusion of zero total event trials in meta-analyses maintains analytic consistency and incorporates all available data","volume":"7","author":"Friedrich","year":"2007","journal-title":"BMC Med. Res. Methodol."},{"key":"B14","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1053\/j.ajkd.2023.08.017","article-title":"Comparative safety and effectiveness of warfarin or rivaroxaban versus apixaban in patients with advanced CKD and atrial fibrillation: nationwide US cohort study","volume":"83","author":"Fu","year":"2024","journal-title":"Am. J. Kidney Dis."},{"key":"B15","doi-asserted-by":"publisher","first-page":"139","DOI":"10.47583\/ijpsrr.2023.v82i02.001","article-title":"Efficacy and safety of apixaban versus warfarin in patients with atrial fibrillation and chronic kidney disease: a randomised controlled trial","volume":"82","author":"Gita Bipin Chandra","year":"2023","journal-title":"Int. J. Pharm. Sci. Rev. Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1160\/TH17-03-0176","article-title":"Dabigatran versus warfarin for acute venous thromboembolism in elderly or impaired renal function patients: pooled analysis of RE-COVER and RE-COVER II","volume":"117","author":"Goldhaber","year":"2017","journal-title":"Thromb. Haemost."},{"key":"B17","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"911","DOI":"10.2147\/CLEP.S219335","article-title":"Differences in gastrointestinal safety profiles among novel oral anticoagulants: evidence from A network meta-analysis","volume":"11","author":"Guo","year":"2019","journal-title":"Clin. Epidemiol."},{"key":"B100","doi-asserted-by":"publisher","first-page":"181","DOI":"10.7326\/M19-0087","article-title":"Benefits and Harms of Oral Anticoagulant Therapy in Chronic Kidney Disease: A Systematic Review and Meta-analysis","volume":"171","author":"Ha","year":"2019","journal-title":"Ann Intern Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"4264","DOI":"10.1007\/s12325-023-02544-8","article-title":"Prescription of DOACs in patients with atrial fibrillation at different stages of renal insufficiency","volume":"40","author":"Hahn","year":"2023","journal-title":"Adv. Ther."},{"key":"B20","doi-asserted-by":"publisher","first-page":"119S","DOI":"10.1177\/0091270011415527","article-title":"Clinical pharmacology basis of deriving dosing recommendations for dabigatran in patients with severe renal impairment","volume":"52","author":"Hariharan","year":"2012","journal-title":"J. Clin. Pharmacol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"B22","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"B23","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1161\/CIRCULATIONAHA.114.012350","article-title":"Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis","volume":"129","author":"Hijazi","year":"2014","journal-title":"Circulation"},{"key":"B24","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1080\/17425255.2023.2287472","article-title":"Pharmacokinetics and pharmacodynamics of direct oral anticoagulants","volume":"19","author":"Hindley","year":"2023","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1056\/NEJMoa1306638","article-title":"Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism","volume":"369","author":"Hokusai","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1253\/circj.cj-12-0899","article-title":"Safety and efficacy of adjusted dose of rivaroxaban in Japanese patients with non-valvular atrial fibrillation: subanalysis of J-ROCKET AF for patients with moderate renal impairment","volume":"77","author":"Hori","year":"2013","journal-title":"Circ. J."},{"key":"B27","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1053\/j.ajkd.2014.01.416","article-title":"KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD","volume":"63","author":"Inker","year":"2014","journal-title":"Am. J. Kidney Dis."},{"key":"B28","doi-asserted-by":"crossref","unstructured":"Oral rivaroxaban for symptomatic venous thromboembolism\n          \n          2499\n          2510\n          10.1056\/NEJMoa1007903\n          N. Engl. J. Med.\n          363\n          2010","DOI":"10.1056\/NEJMoa1007903"},{"key":"B29","doi-asserted-by":"publisher","first-page":"278","DOI":"10.2215\/CJN.02170218","article-title":"Clinical pharmacology of oral anticoagulants in patients with kidney disease","volume":"14","author":"Jain","year":"2019","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1161\/CIR.0000000000001193","article-title":"2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology\/American heart association Joint Committee on clinical practice guidelines","volume":"149","author":"Joglar","year":"2024","journal-title":"Circulation"},{"key":"B31","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.jtha.2023.09.020","article-title":"Anticoagulation in chronic kidney disease: current status and future perspectives","volume":"22","author":"Jones","year":"2024","journal-title":"J. Thromb. Haemost."},{"key":"B32","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ejvs.2020.09.023","article-title":"Editor's choice - European society for vascular Surgery (ESVS) 2021 clinical practice guidelines on the management of venous thrombosis","volume":"61","author":"Kakkos","year":"2021","journal-title":"Eur. J. Vasc. Endovasc. Surg."},{"key":"B33","doi-asserted-by":"publisher","first-page":"e583","DOI":"10.1016\/S2352-3026(20)30211-8","article-title":"Mortality risk associated with venous thromboembolism: a systematic review and Bayesian meta-analysis","volume":"7","author":"Klemen","year":"2020","journal-title":"Lancet Haematol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.jacc.2018.05.066","article-title":"Edoxaban in Asian patients with atrial fibrillation: effectiveness and safety","volume":"72","author":"Lee","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12959-024-00608-5","article-title":"Efficacy and safety of direct oral anticoagulants in patients with atrial fibrillation combined with chronic kidney disease: a systematic review and meta-analysis","volume":"22","author":"Li","year":"2024","journal-title":"Thromb. J."},{"key":"B36","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1007\/s40620-022-01413-x","article-title":"A systematic review of the efficacy and safety of anticoagulants in advanced chronic kidney disease","volume":"35","author":"Parker","year":"2022","journal-title":"J. Nephrol."},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24043169","article-title":"A comprehensive review of risk factors for venous thromboembolism: from epidemiology to pathophysiology","volume":"24","author":"Pastori","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B38","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1161\/CIRCULATIONAHA.121.054990","article-title":"Apixaban for patients with atrial fibrillation on hemodialysis: a multicenter randomized controlled trial","volume":"146","author":"Pokorney","year":"2022","journal-title":"Circulation"},{"key":"B40","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1161\/CIRCULATIONAHA.122.062779","article-title":"A randomized controlled trial comparing apixaban with the vitamin K antagonist phenprocoumon in patients on chronic hemodialysis: the AXADIA-AFNET 8 study","volume":"147","author":"Reinecke","year":"2023","journal-title":"Circulation"},{"key":"B41","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJMoa1113697","article-title":"Extended use of dabigatran, warfarin, or placebo in venous thromboembolism","volume":"368","author":"Schulman","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1161\/CIRCULATIONAHA.119.044059","article-title":"Apixaban versus warfarin in patients with atrial fibrillation and advanced chronic kidney disease","volume":"141","author":"Stanifer","year":"2020","journal-title":"Circulation"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1093\/europace\/euab065","article-title":"European heart Rhythm association practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"23","author":"Steffel","year":"2021","journal-title":"Europace"},{"key":"B44","doi-asserted-by":"publisher","first-page":"e545","DOI":"10.1016\/j.chest.2021.07.055","article-title":"Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report","volume":"160","author":"Stevens","year":"2021","journal-title":"Chest"},{"key":"B45","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.jjcc.2021.08.026","article-title":"Venous thromboembolism: recent advancement and future perspective","volume":"79","author":"Yamashita","year":"2022","journal-title":"J. Cardiol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1615284\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T22:10:21Z","timestamp":1756419021000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1615284\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,29]]},"references-count":46,"alternative-id":["10.3389\/fphar.2025.1615284"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1615284","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,29]]},"article-number":"1615284"}}